According to the National Comprehensive Cancer Network (NCCN) guidelines, a patient with a life expectancy > 5 years should receive EBRT plus ADT plus abiraterone as initial treatment for locally advanced disease. EBRT alone or brachytherapy alone may be used for patients with a life expectancy of > 10 years who are classified as low risk or favorable intermediate risk, according to the NCCN guidelines. SBRT may be used with the appropriate technology, physics, and clinical expertise for limited metastatic disease to the vertebra or paravertebral region when ablation is the goal; or in patients with oligometastatic progression where progression-free survival is the goal; and in patients who have a lesion in or immediately adjacent to a previously irradiated treatment field.
Learn more about radiation treatment of metastatic and advanced prostate cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Evelyn S. Marienberg. Fast Five Quiz: Radiation Therapy for Metastatic and Advanced Prostate Cancer - Medscape - Nov 08, 2022.